Biotech Co.* (Symbol) | Pharma Co. (Symbol/Country) |
Type/Product Area |
Amount (M) |
Terms/Details (Date) |
Affymetrix Inc. |
Sankyo Co. Ltd. (Japan) |
Technology access/access to GeneChip arrays and related technology for gene-expression monitoring | ND | Under EasyAccess Silver agreement, Sankyo gains broad access to GeneChip technology (11/99) |
Aurora Biosciences Corp. | Glaxo Wellcome plc (NYSE:GLX) |
Research collaboration/ion channel drug discovery through access to Aurora's ion channel technologies | ND |
Three-year agreement under which Aurora will provide access to its ion channel technology, including its voltage ion probe reader, the VIPR, its voltage sensor dyes and related assay technology; Aurora will supply assay development, instrumentation and other support (12/99) |
Aurora Biosciences Corp. |
Merck & Co. Inc. (NYSE: MRK) | Research collaborations/functional genomics research using Aurora's GenomeScreen technology to investigate cell signaling pathways and gene function related to selected Merck therapeutic programs | ND | Merck will receive a license to use the data and materials resulting from the program in basic research and drug discovery; Aurora will receive an up-front payment, with the potential for milestones and additional revenues if products are commercialized based on the technology (11/99) |
Aurora Biosciences Corp. |
Wyeth-Ayerst Laboratories (pharmaceutical division of American Home Products Corp.; NYSE:AHP) |
Research collaboration/ion channel drug discovery through access to Aurora's ion channel technologies | ND | Five-year agreement under which Aurora provides access to its ion channel technology, including its voltage ion probe reader, the VIPR, its voltage sensor dyes; Aurora will develop assays for specified ion channels for Wyeth, will deliver instrumentation and will provide ongoing scientific and technical support; financial details ND (12/99) |
Cambridge Antibody Technology (UK) | Searle (pharmaceutical business of Monsanto Co.; NYSE:MTC) | Development collaboration/fully human monoclonal antibody-based drugs across multiple disease areas, focusing particularly on the field of cancer |
$212M |
CAT could receive up to $212M through a $12.5M up-front equity investment, a minimum of $14.5M in research funding, another $35M in various fees and milestones, an additional $150M based on clinical development and regulatory milestones; CAT will also receive royalties on sales of both antibody-based drugs and small-molecule drugs developed by Searle when CAT technology is used to validate a target; both companies will contribute technology, intellectual property and expertise to the project, with CAT generating antibodies to Searle targets (12/99) |
Celera Genomics | Pfizer Inc. (NYSE:PFE) | Database subscription and research collaboration/access to all of Celera's database products and collaboration to discover target genes derived from Celera's sequencing of the human genome | ND | Five-year agreement; Pfizer's access to Celera's isolated full-length genes is non-exclusive; financial details ND (11/99) |
Cephalon Inc. |
Schwarz Pharma (Germany) | Licensing agreement/tyrosine kinase inhibitors for treating prostate and other cancers; includes two compounds in clinical development |
ND | Schwarz will develop and market compounds in Europe and several other territories outside the U.S.; Cephalon will receive up-front license fee, milestones and transfer price on products it manufactures (12/99) < |
Chiron Corp. | Kyokuto Seiyaku Kogyo Inc. (Japan) | Patent litigation settlement/hepatitis C virus immunodiagnostics and antigenic polypeptides | ND | Kyokuto is now prohibited from any manufacture, sale or distribution of HCV antigens or test kits (10/99) |
Cortecs plc (UK) | SmithKline Beecham plc (UK; NYSE: SBH) | License agreement/antigen technology for the development and commercialization of vaccines to prevent diseases caused by Haemophilus influenzae and Moraxella cattarhalis in children |
ND | Cortecs will receive an up-front payment, milestones and royalties on sales (11/99) |
DepoMed Inc. |
Elan Corp. plc (Ireland;NYSE:ELN) |
Joint venture/gastric retention oral delivery technologies and development of products using those technologies |
$5 |
Companies will create joint venture to develop delivery technologies and develop products in undisclosed areas; Elan will invest $5M in DepoMed's common stock and provide R&D funding to the JV (12/99) |
Destiny Pharma* (UK) |
Ciba Vision Corp. (unit of Novartis AG; Switzerland) |
Co-development agreement; photodynamic therapy for ophthalmic diseases | ND |
Ciba gains exclusive global rights to develop photodynamic therapy for ophthalmic diseases; Ciba will pay a series of milestones and royalties and will take over development once the current research program is completed; Destiny retains rights to all other indications (11/99) |
Dyax Corp.* | Pasteur Merieux Connaught (unit of Rhone-Poulenc SA; France) |
Development collaboration/use of Phage Display technology to develop affinity ligands to provide purification of PMC's vaccines |
ND | PMC will fund the research and Dyax will receive milestone payments and royalties on resulting products (10/99) |
Flamel Technologies (France; NASDAQ: FLMLY) |
Novo Nordisk A/S (Denmark; NYSE:NVO) | Licensing and development agreement/Basulin, Flamel's long-acting basal insulin product for diabetes (currently in Phase I trials) |
$42 |
Novo acquires exclusive worldwide marketing rights; Flamel receives up-front licensing fees of $5M, plus $37M in milestones; in addition, Flamel will supply Novo with Medusa nanoparticles for Basulin (12/99) |
Gene Logic Inc. |
Fujisawa Pharmaceutical Co. Ltd. (Japan) |
Database development/use of gene expression information to identify genetic targets for diabetes compounds | ND | Gene Logic will have rights to include data generated in the study in its GeneExpress databases (12/99) |
Genome Therapeutics Corp. |
Wyeth-Ayerst Laboratories (pharmaceutical division of American Home Products Corp.; NYSE: AHP) |
Research collaboration/development of osteoporosis therapies utilizing targets based on characterization of a gene associated with high bone mass trait, the mirror image of osteoporosis |
$118 |
Wyeth-Ayerst will pay Genome Therapeutics an undisclosed upfront fee, fund a multi-year research program, make milestone payments and pay royalties based on sales of therapeutic products developed from the collaboration; if the program runs full term with all milestones met, payments would exceed $118M, excluding royalties (12/99) |
Genzyme Transgenics Corp. |
Bristol-Myers Squibb Co. (NYSE:BMY) | Research collaboration/development of transgenic animals capable of producing undisclosed fusion protein being evaluated for treatment of organ transplant rejection and autoimmune disorders | ND | In the first phase, Genzyme Transgenics will receive development, milestone and maintenance fees while developing transgenic animals; if project succeeds, companies would enter supply agreements for clinical and commercial production (11/99) |
GLYCODesign Inc. (Canada)* |
Seikagaku Corp. (Japan) |
Research collaboration/identification of small-molecule, orally active Core 2 transferase inhibitors for the treatment of inflammation |
$56 |
Seikagaku may select for development up to 3 anti-inflammatory compounds and has the option for an exclusive, worldwide, sublicensable right to intellectual property on compounds selected; GLYCO-Design will receive $8M as an up-front equity investment and research support, $16M for milestones for each compound selected, and royalties on any sales (11/99) |
ID Biomedical Corp. |
Mitsubishi Chemical Corp. (Japan) | Marketing and license agreement/Velogene rapid tests for methicillin-resistant Staphylococcus aureus and Vancomycin-resistant enterococcus, as well as technology for developing additional tests |
ND | Mitsubishi gains non-exclusive rights to market and distribute Velogene rapid tests for MRSA and VRE in Japan, along with a non-exclusive license to use ID's technology in Japan for the development of tests for infectious diseases from blood samples (12/99) |
Interneuron Pharmaceuticals Inc. | Takeda Chemical Industries Ltd. (Japan) | CerAxon (citicoline), a Phase III product under development for ischemic stroke |
$73 | Interneuron will receive $73M in near-term licensing and milestone payments, including $13M in 1999 and $60M for future milestones in the U.S. and Canada; in exchange, Takeda gets exclusive North American commercialization rights; Takeda will also pay royalties to Interneuron, satisfy Interneuron's royatly obligations to Ferrar Internacional S.A., and will fund Phase IV studies in stroke and Phase III trials in other indications (12/99) |
Warner-Lambert Co. (NYSE:WLA) |
License agreement/pagoclone, an anxiolytic drug for the treatment of panic and generalized anxiety | $73.75 | Interneuron could receive up to $73.75M, with $13.75M up front and the rest in milestones; in addition Interneuron will receive royalties on any sales; Warner-Lambert will be responsible for all clinical development, regulatory review, manufacturing and marketing for all indications on a worldwide basis (12/99) | |
Karo Bio AB (Sweden) | Abbott Laboratories (NYSE:ABT) | Research collaboraation/glucocorticoid receptor antagonists targeting the liver as therapies for diabetes |
ND | Abbott gains worldwide marketing rights; Karo receives up-front payments, research funding, milestones and royalties (11/99) |
Lexicon Genetics Inc.* | BASF Bioresearch Corp. (unit of BASF Pharma; Germany) |
Research collaboration/knockout mice creation for validation of target |
ND | Lexicon will create knock-mice based on a gene sequence provided by BASF; financial terms ND (12/99) |
Millennium Predictive Medicine Inc. (MPMx; majority-owned subsidiary of Millennium Pharmaceuticals Inc.) |
Bristol-Myers Squibb Co. (NYSE:BMY) |
Research collaboration/use of pharmacogenomic techniques for new and existing medicines for cancer, along with development of pharmacogenomic diagnostics | $32 |
Five-year alliance to identify and validate oncology clinical markers that can help predict patients' responses to existing drugs and aid in the development of new ones; MPMx will receive $32M in license fees, annual fees and research funding, plus milestones and royalties on any products (11/99) |
Neurochem Inc.* (Canada) |
H. Lundbeck A/S (Denmark) |
Research collaboration/neurological theraapeutics, especially for Alzheimer's disease |
$24.5 | Neurochem will receive research support of up to $7.5M over 3 years and up to $17M in milestones; agreement also calls for additional equity investments in Neurochem and royalties on any sales; Lundbeck has exclusive right to develop and commercialize any products resulting from the project, except in Canada, where Neurochem retained co-commercialization rights (11/99) |
Onyx Pharmaceuticals Inc. |
Warner-Lambert Co. (NYSE:WLA) | Development and marketing agreement/ONYX-105 anti-cancer agent and two additional products |
$155 |
Onyx will receive an up-front and equity investment over 2 years totaling $15M, plus $40M of support for Phase III costs of ONYX-105; in addition to guaranteed money, Onyx could receive up to $100M in milestones for the three products (10/99) |
OXiGENE Inc. (Sweden) | Bristol-Myers Squibb Co. (NYSE:BMY) |
Licensing agreement and research collaboration/combretastatin anti-tumor vascular targeting agents | $70 | BMS licensed worldwide rights to develop compounds in this class, including lead compound Combretastatin A4 Prodrug; BMS will provide up to $70M in licensing fees, including up-front payment, development milestones and research funding, as well as royalties on any sales (12/99) |
Pharmacopeia Inc. |
Otsuka Pharmaceutical Factory Inc. (division of Otsuka Group; Japan) |
Research collaboration/lead discovery services that include assay development |
ND | Pharmacopeia will receive fees, milestones and royalties on marketed products (11/99) |
Pharmacopeia Inc. |
Organon (unit of Akzo Nobel; the Netherlands) |
Screening agreement/screening of 2.7M small molecules against Organon targets |
ND | Pharmacopeia will receive fees for services, milestones and royalties on sales (10/99) |
Photogen Technologies Inc. |
Akorn Inc. (NASDAQ: AKRN) < | Development collaboration/certain formulations of photoreactive compound PH-10, a potential treatment for cancer and certain dermatological conditions | ND | Akorn will help Photogen meet regulatory requirements of the FDA and will develop formulations geared toward various indications; financial terms ND (11/99) |
POZEN Inc.* |
F. Hoffmann La-Roche Ltd. (Switzerland) |
License agreement/novel serotonin (5-HT2B) receptor antagonist discovered by Roche | ND | POZEN acquired exclusive worldwide license and has assumed full responsibility for development, regulatory approval and commercialization; POZEN will pay "certain consideration" upon commercialization; Roche has option to reacquire product at pre-agreed times subject to payment of milestones and royalties to POZEN (11/99) |
Proliferon Inc.* |
SmithKline Beecham plc (UK; NYSE: SBH) | Research collaboration/use of directed combinatorial chemistry libraries and high-throughput screening assays to identify drug candidates | ND | SmithKline gets worldwide rights to develop and market products identified by Proliferon; Proliferon will receive up-front research payments and royalties on sales of pharmaceutical products (11/99) |
Protherics plc (UK; created LLY) |
Eli Lilly and Co. (NYSE: by merger of Proteus International and Therapeutic Antibodies Inc.) |
Licensing agreement and research collaboratiohn/existing Factor Xa inhibitor leads and identification of new ones using Protherics' Computer Aided Design technology | $5 |
During the initial 2 years of the agreement, Protherics may receive more than $5M in initial license fees, research funding and milestones; total payments could be much higher; Protherics would also receive royalties on any sales; financial details ND (12/99) |
Quark Biotech Inc.* | Taisho Pharmaceutical Co. Ltd. (Japan) |
Research and license agreement/identification and analysis of genes and pathways involved in renal diseases< |
ND | Quark has rights to co-market resulting products in North America and the European Union, and is entitled to R&D funding and milestone payments, as well as royalties on any products (12/99) |
Ribozyme Pharmaceuticals Inc. |
Elan Corp. plc (Ireland; NYSE:ELN) |
Joint venture/Herzyme, a ribozyme against human epidermal growth factor receptor Type 2 (HER-2) for treatment of breast and other cancers | ND | Venture will license Elan's MEDIPAD Drug Delivery System for development in conjunction with Herzyme, which is being contributed by Ribozyme; Ribozyme may fund its share of development costs through sale of preferred stock to Elan; in addition, Elan will purchase Ribozyme common stock as part of the agreements; additional details will be disclosed when deal is finalized (12/99) |
Sangamo Biosciences Inc.* | Merck KgaA (Germany) |
Research collaboration/use of Universal GeneTools, which enable rapid generation of highly specific zinc finger DNA binding protein transcription factors that can recognize and regulate target DNA sequence |
ND | Merck will use the technology in its internal research and validation programs; terms were not disclosed (11/99) |
Vertex Pharmaceuticals | Taisho Pharmaceutical Co. Ltd. |
R&D collaboration/discovery and development of caspase inhibitors for treatment of cerebrovascular, cardiovascular and neuro-degenerative diseases; caspases involved in apoptosis will be a focus area |
$43 | Vertex will receive initial payments of $4M, research funding and milestones from Taisho, which will also pay for up to one-third of the cost of developing compounds that emerge from the program; Taisho gains option for marketing rights for any such compound in Japan and certain Far East markets; deal does not include rights to Vertex's ICE (caspase-1) program (11/99) |
ViroPharma Inc. |
Battelle Pulmonary Therapeutics (division of Battelle Memorial Institute*) | License agreement/Batelle's inhalation drug delivery device technology for use in combination with ViroPharma's small-molecule antiviral drug candidates for treating respiratory syncytial virus | ND |
ViroPharma is responsible for development, manufacturing and commercialization of all RSV products; financial terms of license agreement ND (12/99) |
ViroPharma Inc. |
Wyeth-Ayerst Laboratories (pharmaceutical division of American Home Products Corp.; NYSE:AHP) | Development and commercialization agreement/small-molecule antiviral drug candidates for hepatitis C virus | $5 |
Companies will co-promote products and share equally in profits from sales in the U.S. and Canada; in the rest of the world, Wyeth-Ayerst will assume full responsibility for commercialization; ViroPharma will receive up-front fee of $5M, plus milestones, research funding, and equity investments (12/99) |
XTL Biopharmaceuticals Ltd.* (Israel) | F. Hoffmann-La Roche Ltd. (Switzerland) |
Research collaboration/use of Trimera mouse model of hepatitis C to test Roche compounds | ND | Roche will use Trimera to test compounds; financial terms ND (11/99) |
Notes: | ||||
# This chart contains information on new agreements, covering the time between 10/16/99 and 12/31/99. It does not include arrangements that are classified strictly as production, manufacturing, marketing and/or distribution and supply agreements; a chart covering these arrangements appears on page 18. The chart above also does not include any collaborations that involve agricultural product development (which are covered periodically in this publication). A chart covering modified agreements and terminated agreements between big pharma and biotech companies for the same time period (10/16/99 to 12/31/99) will appear in the 02/07/00 issue of BioWorld Financial Watch. | ||||
Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 21-22. | ||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; NM = Nouveau Marche; OTC BB = Over The Counter Bulletin Board | ||||
ND = Not disclosed, reported and/or available | ||||
* Private companies are indicated with an asterisk. | ||||
To read more on related topics, click on one of the words below.